227 related articles for article (PubMed ID: 29915217)
1. Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy.
Clark CA; Mosse CA; Chen H; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Kassim AA; Savani BN; Sengsayadeth S; Jagasia M; Cornell RF
Bone Marrow Transplant; 2018 Dec; 53(12):1589-1592. PubMed ID: 29915217
[No Abstract] [Full Text] [Related]
2. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
[No Abstract] [Full Text] [Related]
3. Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Cohen OC; Counsell N; Rabin N; Popat R; Owen RG; Popova B; Schofield O; Clifton-Hadley L; Lyons-Lewis J; Rawstron A; Spence C; de Tute RM; Hughes D; Moore S; Smith P; Yong KL
Br J Haematol; 2019 Jun; 185(5):948-951. PubMed ID: 30460696
[No Abstract] [Full Text] [Related]
4. The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.
Oortgiesen BE; Azad R; Hemmelder MH; Kibbelaar RE; Veeger NJGM; de Vries JC; van Roon EN; Hoogendoorn M
Haematologica; 2018 Jul; 103(7):e311-e314. PubMed ID: 29545339
[No Abstract] [Full Text] [Related]
5. XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach.
Chanukuppa V; Paul D; Taunk K; Chatterjee T; Sharma S; Kumar S; Santra MK; Rapole S
J Proteomics; 2019 Oct; 209():103504. PubMed ID: 31465861
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27.
Li J; Zhang X; Shen J; Guo J; Wang X; Liu J
Mol Med Rep; 2019 Sep; 20(3):2410-2418. PubMed ID: 31322176
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib improves survival in rare myeloma.
Brower V
Lancet Oncol; 2016 Jun; 17(6):e227. PubMed ID: 27160479
[No Abstract] [Full Text] [Related]
10. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.
Baughn LB; Sachs Z; Noble-Orcutt KE; Mitra A; Van Ness BG; Linden MA
Leuk Lymphoma; 2017 Aug; 58(8):1931-1940. PubMed ID: 27981867
[TBL] [Abstract][Full Text] [Related]
11. Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma.
Iwaki K; Fujiwara T; Ito T; Suzuki C; Sasaki K; Ono K; Saito K; Fukuhara N; Onishi Y; Yokoyama H; Fujimaki S; Tanaka T; Tamura H; Fujiwara M; Harigae H
Tohoku J Exp Med; 2019 Sep; 249(1):19-28. PubMed ID: 31511451
[TBL] [Abstract][Full Text] [Related]
12. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.
Lassalle A; Thomaré P; Fronteau C; Mahé B; Jubé C; Blin N; Voldoire M; Dubruille V; Tessoulin B; Touzeau C; Chauvin C; Loirat M; Lok A; Bourcier J; Lestang E; Mocquet R; Barbarot V; Moreau P
Ann Oncol; 2016 Feb; 27(2):314-8. PubMed ID: 26578729
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-Induced Muscle Toxicity in Multiple Myeloma.
Guglielmi V; Nowis D; Tinelli M; Malatesta M; Paoli L; Marini M; Manganotti P; Sadowski R; Wilczynski GM; Meneghini V; Tomelleri G; Vattemi G
J Neuropathol Exp Neurol; 2017 Jul; 76(7):620-630. PubMed ID: 28863457
[TBL] [Abstract][Full Text] [Related]
14. Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience.
Guo TJ; Huang XJ; Wen L; Lu J
Chin Med J (Engl); 2017 Jan; 130(2):239-241. PubMed ID: 28091419
[No Abstract] [Full Text] [Related]
15. Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma.
Saraceni MM; Scott E; Maziarz RT; Siegel MB; Bassale S; Jiing S; Medvedova E
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e77-e84. PubMed ID: 29169873
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response.
Fukumoto K; Fujisawa M; Suehara Y; Narita KT; Usui Y; Takeuchi M; Matsue K
Leuk Lymphoma; 2016 Aug; 57(8):1786-92. PubMed ID: 26764045
[TBL] [Abstract][Full Text] [Related]
17. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
[No Abstract] [Full Text] [Related]
18. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
[TBL] [Abstract][Full Text] [Related]
19. Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma.
Spaan I; van Nieuwenhuijzen N; Kimman T; Rockx-Brouwer D; Tieland RG; Maurice MM; Minnema MC; Raymakers RA; Peperzak V
Blood Adv; 2023 Apr; 7(7):1103-1107. PubMed ID: 36459495
[No Abstract] [Full Text] [Related]
20. Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.
Watanabe T; Mitsuhashi M; Sagawa M; Ri M; Suzuki K; Abe M; Ohmachi K; Nakagawa Y; Nakamura S; Chosa M; Iida S; Kizaki M
PLoS One; 2015; 10(6):e0128662. PubMed ID: 26115406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
